What 20 Analyst Ratings Have To Say About Biogen

By Benzinga Insights

Biogen (NASDAQ:BIIB) has observed the following analyst ratings within the last quarter:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 4 7 9 0 0
Last 30D 1 0 0 0 0
1M Ago 0 3 3 0 0
2M Ago 0 1 3 0 0
3M Ago 3 3 3 0 0

According to 20 analyst offering 12-month price targets in the last 3 months, Biogen has an average price target of $325.65 with a high of $440.00 and a low of $250.00.

Below is a summary of how these 20 analysts rated Biogen over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the move negative analysts are on the stock

This current average represents a 14.87% increase from the previous average price target of $382.53.

Analyst Ratings: What Are They?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.


What is inkl?

Important stories

See news based on value, not advertising potential. Get the latest news from around the world.

Trusted newsrooms

We bring you reliable news from the world’s most experienced journalists in the most trusted newsrooms.

Ad-free reading

Read without interruptions, distractions or intrusions of privacy.